53
Views
5
CrossRef citations to date
0
Altmetric
Review

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia

, , &
Pages 645-656 | Published online: 07 Feb 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Francesca R. Mauro, Maria D. Caputo, Serena Rosati, Sara Pepe, Daniela De Benedittis, Maria L De Luca & Robin Foà. (2018) Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Review of Hematology 11:8, pages 601-611.
Read now

Articles from other publishers (4)

Dario Valenti, Stanimira Hristeva, Dimitrios Tzalis & Christian Ottmann. (2019) Clinical candidates modulating protein-protein interactions: The fragment-based experience. European Journal of Medicinal Chemistry 167, pages 76-95.
Crossref
Talal Hilal, Juan C. Gea-Banacloche & Jose F. Leis. (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews 32:5, pages 387-399.
Crossref
Barbora Havlíčková. (2018) Autoimunne haemolytic anaemia as a complication of a Chronic Lymphocytic Leukaemia. Interní medicína pro praxi 20:3, pages e9-e14.
Crossref
Joachim R. Göthert, Roze Imsak, Michael Möllmann, Stefanie Kesper, Maria Göbel, Ulrich Dührsen, Arne Scholz, Ulrich Lücking, Matthias Baumann, Anke Unger, Carsten Schultz-Fademrecht, Bert Klebl, Jan Eickhoff, Axel Choidas & Jan Dürig. (2018) Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. Oncotarget 9:41, pages 26353-26369.
Crossref